Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
Illumina blamed "manufacturing and supplier capacity constraints" for weekslong delays seen on orders for certain sequencing reagent kits.
European Commission Objects to Illumina Pushing Through Grail Purchase, Mulls Response
European regulators called Illumina's decision to finalize its purchase of Grail "unprecedented" and said they could ultimately impose financial penalties.
Grail Gets NY State Department of Health Approval for Galleri Multicancer Test
Galleri is designed to detect more than 50 cancer types through a routine blood draw and, when a cancer signal is detected, predict its origin.
Illumina Adds Seven Genomics Startups to Accelerator Program
Through the program, Illumina has invested in 61 companies, which collectively have raised over $1 billion in venture capital to date.
US Federal Court Judge Rules BGI Sequencing Chemistries Infringe Illumina Patents
In an order issued Thursday, Judge William Orrick of the US District Court for the Northern District of California awarded Illumina's request for summary judgement and rebuffed BGI's counterclaim.